Trichothecin Inhibits Cancer-Related Features in Colorectal Cancer Development by Targeting STAT3

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2020 May 20

PMID 32422984

Citations 3

Authors

Xin Qi

Meng Li

Xiao-Min Zhang

Xiu-Fen Dai

Jian Cui

De-Hai Li

Qian-Qun Gu

Zhi-Hua Lv

Jing Li

Affiliations

Soon will be listed here.

Abstract

Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that contributes to cancer progression through multiple processes of cancer development, which makes it an attractive target for cancer therapy. The IL-6/STAT3 pathway is associated with an advanced stage in colorectal cancer patients. In this study, we identified trichothecin (TCN) as a novel STAT3 inhibitor. TCN was found to bind to the SH2 domain of STAT3 and inhibit STAT3 activation and dimerization, thereby blocking STAT3 nuclear translocation and transcriptional activity. TCN did not affect phosphorylation levels of STAT1. TCN significantly inhibited cell growth, arrested cell cycle at the G0/G1 phase, and induced apoptosis in HCT 116 cells. In addition, the capacities of colony formation, migration, and invasion of HCT 116 cells were impaired upon exposure to TCN with or without IL-6 stimulation. In addition, TCN treatment abolished the tube formation of HUVEC cells in vitro. Taken together, these results highlight that TCN inhibits various cancer-related features in colorectal cancer development in vitro by targeting STAT3, indicating that TCN is a promising STAT3 inhibitor that deserves further exploration in the future.

Citing Articles

Oncogenic STAT Transcription Factors as Targets for Cancer Therapy: Innovative Strategies and Clinical Translation.

Wang W, Lopez McDonald M, Hariprasad R, Hamilton T, Frank D Cancers (Basel). 2024; 16(7).

PMID: 38611065 PMC: 11011165. DOI: 10.3390/cancers16071387.

The complementary roles of STAT3 and STAT1 in cancer biology: insights into tumor pathogenesis and therapeutic strategies.

Wang W, Lopez McDonald M, Kim C, Ma M, Pan Z, Kaufmann C Front Immunol. 2023; 14:1265818.

PMID: 38022653 PMC: 10663227. DOI: 10.3389/fimmu.2023.1265818.

Natural Marine Products: Anti-Colorectal Cancer In Vitro and In Vivo.

Han N, Li J, Li X Mar Drugs. 2022; 20(6).

PMID: 35736152 PMC: 9229715. DOI: 10.3390/md20060349.

References

Shabbir A, Cox A, Rodriguez-Menocal L, Salgado M, Van Badiavas E . Mesenchymal Stem Cell Exosomes Induce Proliferation and Migration of Normal and Chronic Wound Fibroblasts, and Enhance Angiogenesis In Vitro. Stem Cells Dev. 2015; 24(14):1635-47. PMC: 4499790. DOI: 10.1089/scd.2014.0316. View

Turkson J . STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets. 2004; 8(5):409-22. DOI: 10.1517/14728222.8.5.409. View

He C, Ai J, Xing W, Chen Y, Zhang H, Huang M . Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells. Acta Pharmacol Sin. 2013; 35(1):89-97. PMC: 4075751. DOI: 10.1038/aps.2013.125. View

Darnell Jr J, Kerr I, Stark G . Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994; 264(5164):1415-21. DOI: 10.1126/science.8197455. View

Barbacid M, Fresno M, Vazquez D . Inhibitors of polypeptide elongation on yeast polysomes. J Antibiot (Tokyo). 1975; 28(6):453-62. DOI: 10.7164/antibiotics.28.453. View

Wang W, Liu H, Wang S, Hao X, Li L . A diterpenoid derivative 15-oxospiramilactone inhibits Wnt/β-catenin signaling and colon cancer cell tumorigenesis. Cell Res. 2011; 21(5):730-40. PMC: 3203668. DOI: 10.1038/cr.2011.30. View

Spitzer R, Jain A . Surflex-Dock: Docking benchmarks and real-world application. J Comput Aided Mol Des. 2012; 26(6):687-99. PMC: 3398190. DOI: 10.1007/s10822-011-9533-y. View

Okusaka T, Ueno H, Ikeda M, Mitsunaga S, Ozaka M, Ishii H . Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma. Hepatol Res. 2015; 45(13):1283-91. DOI: 10.1111/hepr.12504. View

Osugi T, Oshima Y, Fujio Y, Funamoto M, Yamashita A, Negoro S . Cardiac-specific activation of signal transducer and activator of transcription 3 promotes vascular formation in the heart. J Biol Chem. 2001; 277(8):6676-81. DOI: 10.1074/jbc.M108246200. View

10.

Miyoshi K, Takaishi M, Nakajima K, Ikeda M, Kanda T, Tarutani M . Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor. J Invest Dermatol. 2010; 131(1):108-17. DOI: 10.1038/jid.2010.255. View

11.

Aggarwal B, Sethi G, Ahn K, Sandur S, Pandey M, Kunnumakkara A . Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci. 2007; 1091:151-69. DOI: 10.1196/annals.1378.063. View

12.

Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J . AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med. 2015; 7(314):314ra185. PMC: 5279222. DOI: 10.1126/scitranslmed.aac5272. View

13.

Du R, Cui J, Wang T, Zhang A, Tan R . Trichothecin induces apoptosis of HepG2 cells via caspase-9 mediated activation of the mitochondrial death pathway. Toxicon. 2011; 59(1):143-50. DOI: 10.1016/j.toxicon.2011.11.003. View

14.

Bharti A, Donato N, Aggarwal B . Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol. 2003; 171(7):3863-71. DOI: 10.4049/jimmunol.171.7.3863. View

15.

Xu G, Zhang C, Zhang J . Dominant negative STAT3 suppresses the growth and invasion capability of human lung cancer cells. Mol Med Rep. 2011; 2(5):819-24. DOI: 10.3892/mmr_00000178. View

16.

Reilley M, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y . STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. J Immunother Cancer. 2018; 6(1):119. PMC: 6240242. DOI: 10.1186/s40425-018-0436-5. View

17.

Diamantopoulos P, Sofotasiou M, Papadopoulou V, Polonyfi K, Iliakis T, Viniou N . PARP1-driven apoptosis in chronic lymphocytic leukemia. Biomed Res Int. 2014; 2014:106713. PMC: 4137605. DOI: 10.1155/2014/106713. View

18.

Yang J, Liao X, Agarwal M, Barnes L, Auron P, Stark G . Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev. 2007; 21(11):1396-408. PMC: 1877751. DOI: 10.1101/gad.1553707. View

19.

Orlova A, Wagner C, de Araujo E, Bajusz D, Neubauer H, Herling M . Direct Targeting Options for STAT3 and STAT5 in Cancer. Cancers (Basel). 2019; 11(12). PMC: 6966570. DOI: 10.3390/cancers11121930. View

20.

Becker T, Boyd S, Mijatov B, Gowrishankar K, Snoyman S, Pupo G . Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor. Oncogene. 2013; 33(9):1158-66. DOI: 10.1038/onc.2013.45. View